Remedora adds controlled substance prescribing to telehealth platform

Remedora has completed third-party EPCS certification and opened its telehealth platform to controlled substance programs for brands, including Schedule II through V medications. The update lets direct-to-consumer health companies run prescribing, intake, clinician review and pharmacy routing in one system.

Why it matters: - Direct-to-consumer health brands can now offer controlled substance programs on Remedora without stitching together separate prescribing tools. - The change covers Schedule II through V medications, expanding what brands can offer through telehealth. - Remedora says the platform keeps prescribing, patient intake, clinician review and pharmacy routing in one workflow.

What happened: - Remedora added controlled substance prescribing to its telehealth platform for direct-to-consumer health brands. - The platform now supports programs for Schedule II through V medications, including testosterone replacement therapy, modafinil and ketamine. - The launch followed completion of a third-party certification of Remedora's electronic prescribing of controlled substances application by Drummond on Oct. 2, 2026. - Controlled substance programs are available now to new and existing brands on Remedora. - New brands can request a program through Remedora's contact page.

The details: - Federal rules under Drug Enforcement Administration requirements at 21 CFR Part 1311 require an e-prescribing application to pass a third-party audit or certification before it can be used for controlled substances. - The rules also require identity proofing for each prescriber, two-factor authentication at signing, access controls and an audit trail. - Remedora says those controls operate in the same system as patient intake, clinician review and pharmacy routing. - A brand that adds a controlled substance program keeps one platform and one signed business associate agreement instead of connecting separate tools for prescribing. - Remedora does not sell or dispense medication. - Every prescription on the platform requires an evaluation by a licensed clinician with a DEA registration. - Licensed pharmacies fill the prescriptions. - Testosterone and ketamine are Schedule III controlled substances under federal law. - Modafinil is a Schedule IV controlled substance. - Federal telemedicine flexibilities allow clinicians to prescribe controlled medications without a prior in-person visit. - State rules differ, and Remedora publishes a state-by-state guide to telehealth controlled substance rules.

Between the lines: - The certification clears a key compliance hurdle that can slow or block controlled substance telehealth programs. - Bundling identity proofing, signing controls and audit records into one platform may make controlled substance programs easier for brands to launch and manage. - The move also positions Remedora for brands that want to expand beyond standard telehealth prescribing into more tightly regulated treatments.

What's next: - Remedora will continue offering controlled substance programs to brands already on the platform and to new brands that request access. - The company's state-by-state rules guide will remain important because telehealth controlled substance requirements vary by state. - Additional brands may use the platform to launch testosterone, ketamine or modafinil programs under the new certification framework.

The bottom line: - Remedora has turned its telehealth platform into a compliant path for controlled substance prescribing, which could make regulated telehealth programs easier to launch and operate.